Review on Interferon beta: from cells to clinical usage
Authors
Abstract:
Introduction: Interferon (IFN) was first introduced by Isaacs and Linddeman in 1957. It referred to a factor that could cause inhibition in the growth of the live influenza virus. Interferons are intracellular proteins that are involved in many cellular processes such as growth, proliferation, differentiation, metabolism of the extracellular matrix, apoptosis, and regulating immune responses. There are different intereferones. Amog them, interferons-beta (IFN-β) is a natural cytokine produced by immune cells in response to biological and chemical stimuli. Signal transduction of IFN-β is initiated throughout a heterodimeric receptor complex that is composed of IFNAR1 and IFNAR2; which leads to expression of various proteins via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway as well as other pathways. In addition to antiviral effects of IFN-β, it has been shown to have therapeutic effects in some autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and lupus. It has recently been shown that the use of IFN-β in combination with other antiviral compounds may be effective in treatment of Covid-19. In this review the various topics about IFN-β are investigated such as signalling pathways, biological functions, therapeutic effects, and side effects of IFN-β therapy.
similar resources
The Effect of Beta Interferon on Dendritic Cells and Cytokine Synthesis by CD4+ T Cells
Background: Dendritic cells (DC) are a key regulator of the immune response, and interferon- beta (IFN-β) is considered an immunomodulatory molecule for DC. Objective: The purpose of this study was to evaluate the ability of IFN-β treated DC to induce cytokine secretion by CD4+ T cells. Methods: Dendritic cells were generated from blood monocytes with granulocyte-monocyte colony-stimulating fac...
full textProperties of non-glycosylated human interferon-beta from MG63 cells.
MG63 cells induced by Sendai virus produce human interferon (IFN)-beta with a molecular weight of 22000. In the presence of tunicamycin, they produced non-glycosylated, biologically active, IFN-beta with a molecular weight of 17000. It had slightly lower heat stability (at 56 degrees C) than normal glycosylated IFN, but the sensitivity to neutralization by antisera and the cross-species activit...
full textCharacterization of human beta-interferon-binding sites on human cells.
Radioiodinated recombinant human beta-interferon (rHuIFN beta Ser), with almost full (greater than 90%) biological activity, was used to study the binding of human beta-interferon to Daudi cells. Specific binding was not observed with less biologically active (less than or equal to 10%) radioiodinated interferon. The bound radioiodinated interferon was shown to compete with human beta-interfero...
full textExpression Analysis of Interferon Beta Level in HEK293T Cells Using Real-Time PCR and Protein Tests
Background: Interferons are some kind of natural cytokines which express in response to a variety of antigens including viral RNA, bacterial products, and tumor proteins. Interferon beta is used in the treatment of autoimmune diseases such as multiple sclerosis. Moreover, this drug inhibits cellular proliferation as well as angiogenesis and as a result, helps to cure cancer. In this research, i...
full textInterferon signalling in pancreatic beta cells.
Type 1 diabetes results from apoptotic destruction of insulin-producing beta cells by a range of effector molecules produced by immune cells that infiltrate pancreatic islets. Interferons are found within the inflammatory infiltrate of islets during progression to type 1 diabetes. Interferons can promote the action of effector cells that induce beta cell death. They can also act directly on isl...
full textFingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
full textMy Resources
Journal title
volume 24 issue 1
pages 26- 37
publication date 2022-01
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023